水野卓、川合正允,賴慶亮譯。1997。菇類的化學、生化學。國立編譯館,台北。
今關六也、本鄉次雄。1957。原色日本菌類圖鑑。保育社,東京。
王怡凱、王緯書、周月卿、劉俐婷。2008。轉移性大腸癌病例之用藥探討。醫院藥學,25,128-132。行政院衛生署。2013。行政院衛生署衛生統計資料網。
徐麗嵐。2002。以柳松菇與鴻喜菇誘導人類白血病細胞(U937)分化及對Balb/c鼠皮下移植CT26腫瘤之抑制效果。國立台灣大學食品科技研究所碩士論文。徐素琴。2007。台灣山豆根根部粗抽物誘導人類肝癌細胞 (Hep3B)細胞週期停滯、細胞凋亡與抑制轉移之分子機轉。中國醫藥大學中國藥學研究所博士論文。高明見。2007。免疫系統與細胞免疫療法。遠東聯合診所期刊。
陳光耀。1972。癌病淺說。科學月刊,3,13-14。科學月刊社,台北。陳勁初、黃仕政。2000。菇菌類機能性食品之開發。生物產業 ,11(3),164-172。陳品玲、林美良、林佳靜、張鶴齡、羅琦、馮清淳、鄭春秋。2008。成人
內外科護理上冊,第四版,p535。華杏,台北。
陳秋慧。2005。癌症化學治療及護理。癌症護理學,華杏,台北。
陳建男。2010。玉皇菇中一種新免疫調節蛋白之純化與其生理活性之研究。國立台灣大學食品科技研究所博士論文。張雅筑。2012。鴻喜菇蛋白質對人類肝癌細胞 (HepG2) 生長抑制及細胞週期停滯之研究。國立台灣大學食品科技研究所博士論文。郭志鎰。2001。大腸直腸癌致癌機轉之研究。中山醫學大學生物化學研究
所碩士論文。
趙大中。2008。轉移性大腸直腸癌的標靶治療。臨床醫學,6,99-104。葉怡柔、林水木、許峯旗、林逸祥、簡素玉。2009。大腸直腸癌之藥物治療。藥學雜誌,101,93-95。鄭武飛。1989。免疫细胞膜分子(二)。醫學免疫學。北京,人民衛生出版社。
歐馨婷。2001。多種蔬菜抑制人類白血病細胞U937增殖與誘導其分化之探討。國立台灣大學食品科技研究所碩士論文。蔡慧思、魏聖修、劉俊坤、許健成。2010。基質金屬蛋白酶-2,9 與腫瘤細胞轉移
之重要性。醫檢會報,25,48-55。
簡佳怡。2005。鴻喜菇蛋白質對小鼠大腸癌CT26細胞生長抑制機制及對Balb/c鼠之該腫瘤轉移效果。國立台灣大學食品科技研究所碩士論文。蔣軍廣、王麗華、譚偉麗、陳秋生、帖永新、翟建華、趙娜。2008。N-cadherin在非小細胞肺癌組織中的表達及臨床意義。中國腫瘤臨床,35,96-99。
謝銘鈞。2004。大腸癌當代醫學,3,953-959。潘函君。2008。探討人類乳癌細胞中 P0 及 GCIP 蛋白和 tumor progression 之關係。國立成功大學生物科技研究所碩士論文。
謝佳瑛、宋慧蒂、陳芳婷、陳彥仰。2007。大腸直腸癌的標靶治療。長庚
藥學學報,14,4-9。
癌症問答。2007。http://www.cancerquest.org/index.cfm?page=399&lang=tchinese
轉移介紹。2004。http://www.oxygentimerelease.com/A/Disorders/p24.htm
醫源世界。2007。惡性腫瘤的生成。
Abdalla, E. K.; Vauthey, J. N.; Ellis, L. M.; Ellis, V.; Pollock, R.; Broglio, K. R.; Hess, K.; Curley, S. A. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004, 239, 818-825.
Abid, M. R.; Yi, X.; Yano, K.; Shih, S. C.; Aird, W. C. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res. 2006, 72, 136-145.
American cancer society: Colorectal cancer facts & figures. American cancer society. Atlanta. 2011.
Bozzuyo, G.; Molinri, A. Molecular aspects of tumor cell migration and invasion. Ann. Ist. Super. Sanita. 2010, 46, 66-80.
Cheung, P. C. Plasma and hepatic cholesterol levels and fecal neutral sterol excretion are altered in hamsters fed straw mushroom diets. J. Nutr. 1998, 222, 687-688.
Chang, J. S.; Son, J. K.; Li, G.; Oh, E. J.; Kim, J. Y.; Park, S. H.; Bae, J. T.; Kim, H. J.; Lee, I. S.; Kim, O. M.; Kozukue, N.; Han, J. S.; Hirose, M.; Lee, K. R. Inhibition of cell cycle progression on HepG2 cells by hypsiziprenol A9, isolated from Hypsizigus marmoreus. Cancer Lett. 2004, 212, 7-14.
Dolley, C. M.; McEwan, J. R.; Henney, A. M. Matrix metalloproteinases and vardiovascular disease. Circ Res. 1995, 77, 863-868.
Deryugina, E. I.; Quigley, J. P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25, 9-14.
Fishman, D. A.; Liu, Y.; Ellerbroek, S. M.; Stack, M. S. Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells. Cancer Res. 2001, 61 , 3194-3199.
Gory, S.; Dalmon, J.; Prandini, M. H.; Kortulewski, T.; Huber, P. Requirement of a GT box (Sp1 site) and two Ets binding sites for vascular endothelial cadherin gene transcription. J Biol Chem. 1998, 273, 6750-6755.
Gulhati, P.; Bowen, K. A.; Jianyu , Stevens, P. D.; Rychahou, P. G.; Chen, M.; Lee , E. Y.; Weiss, H. L.; O’Connor, K. L Gao, T.; Evers, B. M. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011, 71 , 3246-3256.
Hikino, H.; Ishiyama, M.; Suzuki, Y.; Konno, C. Mechanisms of hypoglycemic activity of Ganderan B: a glycan of Gandoderma lucidum fruit bodies. Planta Med. 1989, 55, 423-428.
Huhtala, P.; Tuuttila, A.; Chow, L.T.; Lohi, J. Complete structure of the human
gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J. Biol. Chem. 1991, 266, 16485–16490.
Howell, G. M.; Humphrey, L. E.; Awwad, R. A. Aberrant regulation of transforming growth factor-alpha during the establishment of growth arrest and quiescence of growth factor independent cells. J Biol Chem. 1998, 273, 9214.
Harvey, L.; Arnold, B.; Lawrence, Z.; Paul, M.; David, B.; James, D. Molecular cell biology, 4rd edition; 1999, p.1060.
Hendrix, M. J.; Seftor, E. A.; Hess, A. R.; Seftor, R. E. Molecular plasticity of human melanoma cells. Oncogene. 2003, 22, 3070-3075.
Haijuan,Y.; Derek, G.; Rudge, J.; Bhamini, V.; Hyo, Y.; Nikola, P. mTOR kinase structure, mechanism and regulation. Nature. 2013, 497,217-224.
Iwamuro, Y.; Aoki, M.; Mikami, Y. J. Ferment Technol. 1985, 63, 61-66.
Ikekawa, T.; Saitoh, H.; Feng, W.; Zhang, H.; Li, L.; Matsuzawa, T. Antitumor activity of Hypsizigus marmoreus. I. Antitumor activity of extracts and polysaccharides. Chem. Pharm. Bull. 1992, 40, 1954-1957.
Iozzo, R.V.; Cohen, I. Altered proteoglycan gene expression and the tumor stroma. Experientia. 1993, 49, 447-455.
Iwatsuki, M.; Mimori, K.; Yokobori, T.; Ishi, H.; Beppu , T.; Nakamori, S.; Baba, H.; Mori, M. Epithelial–mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2009, 101 , 293-299.
Jiang, D.; Yang, H.; Willson, J. K. Autocrine transforming growth factor alpha provides a growth advantage to malignant cells by facilitating re-entry into the cell cycle from suboptimal growth states. J Biol Chem. 1998, 273, 31471.
Joyce, E. R. Matrix metalloproteinases and angiogenesis. J. Cell. Mol. Med. 2005, 9, 267-285.
Kazutaka, T.; Yutaka, A.; Shoji, O.; Takashi, M.; Mamoru, I. Isolation of novel collagen-binding protein from the mushroom, Hypsizigus marmoreus, which inhibits the Lewis Lung carcinoma cell adhesion to Type IV collagen. J Biol Chem. 1995, 270(4), 1481-1484.
Kelloff, G. J.; Schilsky, R. L.; Alberts, D. S.; Day, R. W.; Guyton, K. Z.; Pearce, H. L.; Peck, J. C.; Phillips, R .; Sigman, C. C. Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs. Clin Cancer Res. 2004, 10, 3908-3918.
Lieu, C.W.; Lee, S. S.; Wang, S.Y. The effect of Ganoderma lucidum on induction of differentiation in leukemic U937 cells. Anticancer Res. 1992, 12, 1211-1216.
Lam, S. K.; Ng, T. B. Hypsin, a novel thermostable ribosome-inactivating protein with antifungal and antiproliferative activities from fruiting bodies of the edible mushroom Hypsizigus marmoreus. Biochem. Biophys. Res. Commun. 2001, 285, 1071-1075.
Mohammed, F. F.; Smookler, D. S.; Khokha, R. Metalloproteinases, inflammation, and rheumatoid arthritis. Ann Rhum Dis. 2003, 62, 43-47.
Milli, A.; Perego, P.; Beretta, G. L.; Corvo, A.; Righetti, P. G.; Carenini, N.; Corna, E.; Zuco, V.; Zunino, F.; Cecconi, D. Proteomic analysis of cellular response to novel proapoptotic agents related to atypical retinoids in human IGROV-1 ovarian carcinoma cells. J Proteome Res. 2011, 10, 1191-1207.
Nagase, H.; Woessner, J. F. Matrix metalloproteinases. J Biol Chem. 1999, 274,
21491–21494.
Nakai.; R, Masui.; H, Horio.; H, Ohtsuru.; M. Effect of maitake (Grifola frondosa) water extract on inhibition of adipocyteconversion of C3H10T1/2B2C1 cells. J Nutrition SciVitaminol. 1999, 45, 385-389.
Nguyen, M.; Arkell, J.; Jackson, C. J. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol. 2001, 33, 960-970.
Obrocea, F.; Sajin, M.; Marinescu, E.; Stoica, D. Colorectal cancer and the 7th revision of the TNM staging system: review of changes and suggestions for uniform pathologic reporting. Rom J Morphol Embryol. 2011, 52, 537-544.
Peng, B. Suppression of human ovarian SKOV-3 cancer cell growth by Duchesnea phenolic fraction is associated with cell cycle arrest and apoptosis. Gynecol Oncol. 2008, 108, 173-181.
Roy, R.; Zhang, B.; Moses, M. A. Making the cut: proteasemediated regulation of
angiogenesis. Exp Cell Res. 2006, 312, 608-622.
Rychahou, P. G.; Jackson, L. N.; Silva, S. R.; Rajaraman, S.; Evers, B. M. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma. Ann Surg. 2006, 243, 833-842.
Sopata, J. A latent gelatin specific proteinase of human leucocytes and its
activation. Biochim. Biophys. Acta. 1979, 571, 305–312.
Sichel, G.; Corsaro, C.; Scalia, M.; Bilio, A. J.; Bonomo, R. P. In vitro scavenger activity of some flavonoids and melanins against O2. Free Radical Biology and Medicine . 1991, 11, 1-8.
Saitoh, H.; Feng, W. J.; Matsuzawa, T.; Ikekawa, T. Antitumor activity of Hypsizigus marmoreus. II. Preventive effect against lung metastasis of Lewis lung carcinoma. Yakugaku Zasshi. 1997, 117, 1006-1010.
Shoji, Y.; Isemura, M.; Muto, H.; Isemura, S.; Aoyagi, Y. Isolation of a 41-kda protein with cell adhesion activity for animal tumor cells from the mushroom hypsizigus marmoreus by affinity chromatography with type iv collagen immobilized on agarose. Biosci Biotechnol Biochem. 2000, 64(4), 775-780.
Sternlicht, M.; Coussens, L.; Vu, T. H.; Werb, Z. Biology and regulation of the matrix metalloproteinases. In Cancer drug discovery and development: Matrix metalloproteinase inhibitors in cancer therap . Humana Press Inc.2000,1-37.
Sawhney, R. S.; Zhou, G. H.; Humphrey, L. E. Differences in sensitivity of biological functions mediated by epidermal growth factor receptor activation with respect to endogenous and exogenous ligands. J Biol Chem. 2002, 277, 75-80.
Suyama, K.; Shapiro, I.; Guttman, M. A signaling pathway leading to metastasis is controlled by N-cadherin and FGF receptor. Cancer Cell. 2002, 24, 301-314.
Stefanidakis, M.; Koivunen, E. Cell-surface association between matrix
metalloproteinases and integrins: role of the complex in leukocyte migration and cancerprogression. Blood. 2006, 108, 1441-1450.
Sehgal, S. N. Its discovery, biological properties, and mechanism of action. Transplant Proc. 2003, 35, 7-14.
Tam, S. C.; Yip, K. P.; Fung, K. P.; Chang, S.T. Hypotensive and renal effects of an extract of the edible mushroom Pleurotus sajor-caju. Life Sci. 1986, 38, 1155-1161.
Vu, T. H.; Werb, Z. Matrix metalloproteinases: effectors of development and normal physiology. Gene. 2000, 14, 2123-2133.
Wang, J.; Sun, L.; Myeroff, L.; Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem.1995; 270, 22044.
Wang, H. X.; Ooi, V. E.; Ng, T. B.; Chiu, K. W.; Chang, S. T. Hypotensive and vasorelaxing activities of a lectin from the edible mushroom Tricholoma mongolicum. Pharm Toxicol. 1996, 79, 318-323.
Wang, J. J.; Lee, J. Y.; Chen, Y. C.; Chern, Y. T.; Chi, C.W. The antitumor effect of a novel differentiation inducer, 2, 2-Bis (4-(4-amino-3-hydroxyphenoxy) phenyl) adamantane (DPA), in combinatory therapy on human colon cancer. Int J Oncol . 2006, 28, 1003-1012.
Wallerand, H.; Robert, G.; Pasticier, G.. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol Semin Invest. 2010, 28, 473-479.
Yamamoto, Y.; Shirono, H.; Kono, K.; Ohashi, Y. Immunopotentiating activity of the water-soluble lignin rich fraction prepared from LEM-the extract of the solid culture medium of Lentinus edodes mycelia. Biosci Biotechnol Biochem. 1997, 61, 1909-1912.
Vartio, T.; Vaheri, A. A gelatin-binding 70,000-dalton glycoprotein synthesized
distinctly from fibronectin by normal and malignant adherent cells. J. Biol. Chem. 1981, 256, 13085–13090.
Van, P. E.; Dubois, B.; Nelissen, I. Rudd, P.M. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev.Biochem. Mol. Biol. 2002, 37, 375–536.
Vihinen, P.; Kahari, V. M.; Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets. Int J Cancer. 2002, 99, 157-166.